Pfizer/Sanofi’s Exubera May Need More Data In Asthma, COPD Patients

Pfizer/Sanofi-Aventis' inhaled insulin powder Exubera may need additional information on pulmonary effects in patients with asthma and chronic obstructive pulmonary disease, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Sept. 8